ST. JOSEPH, Mich., July 28 GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant to develop an integrated systems pharmacology platform for pharmacogenomic research. The SBIR grant, funded through the innovations in biomedical computational science and technology initiative, will be used to develop a database and systems biology tool-set specifically designed for the study of mutations and sequence heterogeneity in human genes and their controlling regions, as well as the biological consequences of sequence variations on disease susceptibility and drug response.
"Genome-wide association studies and next-generation resequencing projects are already generating vast amounts of data on genetic factors contributing to disease susceptibility and variability in the pharmacological and toxicological effects of drugs," said Richard Brennan, Director of Toxicology at GeneGo and PI on the grant. "What is lacking are powerful tools for researchers to be able to link these sequence variations to the specific mechanisms and biological pathways driving idiosyncratic outcomes. The product will smooth the progress of personalized medicine by facilitating the application of personal genetic profiling to identify optimal therapeutic strategies."
"Receiving such a prestigious grant award is another example of the cutting edge research at GeneGo that sets us apart from other companies," said Julie Bryant, GeneGo's VP of Business Development. "It allows us to develop novel tools and databases to help our customers mine important content from the literature, analyze their data and test their hypotheses."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.4(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site at www.genego.com.
SOURCE GeneGo, Inc.